PD-L1 (also known as CD274) is considered an immune checkpoint is facilitating anti-tumor suppression of the immune pathway.
How has PD-L1 NSCLC impacted people’s lives?
- Total cases of Programmed death-ligand 1 (PD-L1) mutated NSCLC in 7MM was 242,014 in 2017.
- Programmed death-ligand 1 (PD-L1) NSCLC cases in the United States in 2017 was 89,597.
- Programmed death-ligand 1 (PD-L1) NSCLC cases in Spain in 2017 was 11,585.
How will Disease transform PD-L1 NSCLC Market?
Pembrolizumab has received US Food and Drug Administration (FDA) approval for the frontline treatment of metastatic nonsquamous NSCLC in combination with pemetrexed and carboplatin, irrespective of programmed cell death ligand 1 (PD-L1) expression. This combination is the most preferred treatment option for those with PD-L1 expression <50% or unknown advanced adenocarcinomas. However, atezolizumab with carboplatin and taxane-based regimens are also appropriate and have regulatory approval in this setting as well. The combination of platinum-based doublet chemotherapy, bevacizumab, and atezolizumab is a potential alternative in patients with nonsquamous NSCLC, and it has received FDA approval for this indication.
“Programmed death-ligand 1 (PD-L1) mutated NSCLC market size in 7MM was USD 6,536 million in 2017″.
Many drivers and barriers will influence the PD-L1 mutated NSCLC market.
- Increasing Use of Biomarker Testing
- Increase in the Mutation Specific Trials Activity
- Increasing Incidence of Programmed death-ligand 1 (PD-L1) mutated NSCLC
- Cost-Effectiveness of Therapies
- Cost of Therapies
- Burden of Disease
Which biotechnical companies are developing PD-L1 NSCLC drugs?
The dynamics of the Programmed death-ligand 1 (PD-L1) mutated NSCLC market is anticipated to change in the coming years owing to the rise in numbers of company’s taking an interest in the development of specific drugs for Programmed death-ligand 1 (PD-L1)
mutated NSCLC, along with increasing awareness and knowledge towards this mutation.
Key players, such as Canakinumab (ACZ885): Novartis Pharmaceutical, Avelumab (Bavencio): Merck KGaA and Pfizer; Libtayo (Cemiplimab): Regeneron Pharmaceuticals; M7824 (Bintrafusp alfa): GlaxoSmithKline/Merck KGaA and others are involved in developing drugs for Programmed death-ligand 1 (PD-L1) mutated NSCLC.
Request for sample pages @ PD-L1 NSCLC Market Landscape